October 17, 2011
Ube Industries and Santen Pharmaceutical announced on October 14 that the two companies have entered into a license and collaboration agreement for the ophthalmic treatment EP2 Agonist DE-117, which has been developed by Ube. Under the terms of the agreement,...read more